Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine

• Main Authors: Lallemant M., Ngo-Giang-Huong N., Jourdain G., Traisaithit P., Cressey T.R., Collins I.J., Jarupanich T., Sukhumanant T., Achalapong J., Sabsanong P., Chotivanich N., Winiyakul N., Ariyadej S., Kanjanasing A., Ratanakosol J., Hemvuttiphan J., Kengsakul K., Wannapira W., Sittipiyasakul V., Pornkitprasarn W., Liampongsabuddhi P., Mcintosh K., Van Dyke R.B., Frenkel L.M., Koetsawang S., Le Coeur S., Kanchana S.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-77749282888&partnerID=40&md5=e529099b0670c177dc96ef72266e4240; http://cmuir.cmu.ac.th/handle/6653943832/866
• Institution: Chiang Mai University

Background. Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks...